Business Wire

1E

1.10.2020 13:16:05 CEST | Business Wire | Press release

Share
IT Departments that aren’t Listening to Employees Will Fail in 2021, says 1E

Endpoint automation leader 1E has announced new features to their market leading digital experience management offering, Tachyon Experience, helping enterprises truly understand how users experience their IT.

Sentiment as a leading indicator in a Remote First World

In a remote first world, knowledge workers increasingly rely on their endpoint to be performant and responsive; The endpoint is their entire conduit to the workplace. Recent research by Vanson Bourne showed that the overwhelming majority (98%) of remote workers found endpoint performance to be important, yet more than half (53%) saying that their machine runs more slowly outside the office. IT has historically lacked the tools to identify and remediate these issues. Tachyon Experience has been built to provide IT analytics of the aggregated digital experience of users across the entire endpoint estate down to the sentiment of an individual user.

“Almost every knowledge worker is working remotely, but they have an inferior experience to working in the office. Businesses that succeed in a remote first world will provide a first class digital experience to all employees wherever they are. IT departments need tools which monitor digital experience, gather employee sentiment and remediate issues as they happen.” said Sumir Karayi, CEO and Founder, 1E

Tachyon Sentiment joining up previously siloed datasets

Integration is where Tachyon Sentiment differentiates over the traditional survey approach; Traditionally, IT departments have conducted periodic NPS polls, but this has rarely been joined up to the applications and device they’re using. This siloed approach to data clouds any real digital experience insights. For the first time, IT departments are able to correlate a user’s sentiment or perception of IT with actual telemetry from the endpoint that they’re using. Tachyon Experience aggregates end user sentiment with endpoint metrics (stability, performance and responsiveness) into a single, overarching Digital Experience score.

“Sentiment is a vital expansion to our Tachyon Experience offering as it allows IT departments the ability to identify users that appear to be having a solid experience from a technical metrics perspective, but in reality, are having a frustrating time with some of their applications or day to day end point experience”, says Rob Peterscheck, VP of Product for 1E

The new Sentiment capability in 1E Tachyon Experience introduces unparalleled flexibility and integration in comparison to traditional approaches to gathering user feedback. Users can be polled on an ad-hoc basis, scheduled or in response to a specific event (for example an IT change or upgrade). “The ability to collect user feedback in real time in response to major transformation initiatives or rollouts will also be a major asset to IT operations teams who have previously used trailing indicators such as escalation of service desk tickets” said Peterscheck.

Digital Experience, not just the purview of the IT department

The addition of Sentiment to Tachyon Experience marks a vital step in a market shift to broaden the appeal of Digital Experience Monitoring tools beyond the IT department. “Given the challenges of remote working for employees and the tighter relationship between HR and IT, we see the Tachyon Experience playing a part in further desiloing data and toolsets between our departments. HR routinely ask employees how they feel about their workplace using traditional tools, but in this new world, the laptop is their workplace and hence it makes sense to share the data between the departments” said Nick Bartlett, Chief People Officer for 1E

For more information on 1E Tachyon Experience, attend the launch webinar on 15th of October at https://info.1e.com/tachyon-sentiment-launch or visit www.1E.com .

Statistics referenced throughout are taken from 1E’s latest research ‘The new digital workplace: employee experiences with universal remote working since COVID’. You can read the full research here: www.1E.com/wfa-research

####

About 1E

1E offers the only real-time remote endpoint automation solution that helps IT actively manage employee experience in real-time. Giving IT teams total control and visibility over all remote endpoints, Tachyon offers in-depth analytics to understand and improve the experience employees have with their endpoints. It delivers

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye